

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

MOC2

RRID:CVCL_ZD33

Type: Cell Line

Proper Citation

RRID:CVCL_ZD33

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_ZD33

Proper Citation: RRID:CVCL_ZD33

Description: Cell line MOC2 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Squamous cell carcinoma of the mouse oral cavity

Defining Citation: [PMID:22086849](#), [PMID:22434099](#), [PMID:24668645](#), [PMID:25729643](#)

Comments: Characteristics: Agressive growth phenotype.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MOC2

Synonyms: Mouse Oral Cancer 2

Cross References: GEO:GSM1213080, GEO:GSM1213081, GEO:GSM1213082, Kerafast:EWL002-FP, Millipore:SCC470, Wikidata:Q98127271

ID: CVCL_ZD33

Record Creation Time: 20220427T220816+0000

Record Last Update: 20260829T234648+0000

Ratings and Alerts

No rating or validation information has been found for MOC2.

No alerts have been found for MOC2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

McIlvried LA, et al. (2026) CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma. *Cell reports*, 45(2), 116994.

Chen F, et al. (2026) CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(11), 2166.

Patra M, et al. (2026) SIRT2 mitigates radiation-induced oral mucositis by promoting homologous recombination-mediated DNA double-strand break repair in epithelial stem cells. *Cancer letters*, 640, 218239.

Liu L, et al. (2026) A Dual-Responsive Versatile Nanohybrid Orchestrating Tumor Elimination and Tumor-Associated Osteolysis Restoration via Sequential Release. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(30), e18962.

Min Y, et al. (2026) ZBP1 Drives CD8+ T cell-mediated anti-tumor immunity in head and neck squamous cell carcinoma. *PLoS genetics*, 22(5), e1012107.

Durmus GT, et al. (2026) Resolvin E1 and Maresin 1 Attenuate Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3-Associated Inflammation and Invasion in Oral Squamous Cell Carcinoma. *The American journal of pathology*, 196(8), 1777.

Liu W, et al. (2026) DDX24 exacerbates inflammation-induced immunosuppression in oral squamous cell carcinoma progression through IL-17 signaling pathway. *Archives of oral biology*, 188, 106639.

Tsai TY, et al. (2026) The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors. *Translational oncology*, 70, 102839.

Singh A, et al. (2026) Converting focused ultrasound-based boiling histotripsy into a systemic cancer vaccine using antigen-capturing microparticles. *Theranostics*, 16(12), 7007.

Yang J, et al. (2025) Blocking the TCA Cycle in Cancer Cells Potentiates CD36+ T-cell-Mediated Antitumor Immunity by Suppressing ER Stress-Associated THBS2 Signaling. *Cancer research*, 85(11), 2014.

Kano M, et al. (2025) Combined CD25-targeted near infrared photoimmunotherapy (NIR-PIT) and intratumor IL-15 enhance the effectiveness of anti-PD-1 immunotherapy. *Cancer immunology, immunotherapy : CII*, 75(1), 7.

Kassir MF, et al. (2025) Alzheimer's Disease-Associated Amyloid Beta Precursor Protein Prevents Aging Stress-Induced Mitophagy and Fumarate Depletion to Improve Anti-Tumor Immunity. *Cancer research*.

Mulpuri Y, et al. (2025) TRPV4 activation in Schwann cells mediates mechanically induced pain of oral cancer. *Frontiers in pain research (Lausanne, Switzerland)*, 6, 1532885.

Bopp AR, et al. (2025) Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. *Cancer immunology, immunotherapy : CII*, 74(7), 227.

Ross RB, et al. (2024) PPAR α Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1916.

Saito S, et al. (2024) Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1934.

Heath BR, et al. (2023) Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. *Cell reports*, 42(4), 112303.

Kato T, et al. (2023) Near-Infrared Photoimmunotherapy Targeting Podoplanin-Expressing Cancer Cells and Cancer-Associated Fibroblasts. *Molecular cancer therapeutics*, 22(1), 75.

Son GY, et al. (2023) The Ca²⁺ channel ORAI1 is a regulator of oral cancer growth and nociceptive pain. *Science signaling*, 16(801), eadf9535.

Forti KM, et al. (2023) Tumoral P2Y₂ receptor modulates tumor growth and host anti-tumor immune responses in a syngeneic murine model of oral cancer. *Purinergic signalling*.